骨髓增生异常综合征的分子病理生理学:靶向治疗的启示
本文综述骨髓增生异常综合征(MDS)的突变与生物学全景及针对这些特征的临床试验靶向治疗,指出仅来那度胺针对del(5q)亚群、阿扎胞苷和地西他滨两种表观遗传调节剂获批,并讨论化疗敏感性与计算机信号网络筛选等个体化治疗策略。
要点
- MDS临床异质性与分子异常谱相关,但靶向治疗选择有限。
- 仅来那度胺针对del(5q)亚群,阿扎胞苷和地西他滨为获批表观遗传调节剂。
- 化疗敏感性与计算机信号网络筛选可能辅助确定个体化治疗。
核心结论
- MDS分子复杂性高而有效治疗药物有限,互补的化疗敏感性与计算机信号网络筛选等新方法结合下一代分子技术,可能有助于实现更优、更选择性的治疗。
研究设计与样本
- 综述,回顾MDS的突变与生物学全景及当前临床试验中的靶向治疗,并讨论个体化治疗筛选策略。
主要发现
- MDS临床异质性与该疾病谱内近期识别的多种分子异常相关。
- 仅来那度胺特别针对del(5q)细胞遗传学这一特定临床患者亚群,阿扎胞苷和地西他滨两种表观遗传调节剂已获批用于治疗这些患者。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The clinical heterogeneity of the myelodysplastic syndromes (MDSs) relates to the recently discerned panoply of molecular abnormalities extant within this disease spectrum. Despite increasing recognition of these biologic abnormalities, very limited therapeutic options exist to exploit our increasing understanding of the molecular pathophysiology of MDS, with only 1 therapy (lenalidomide) particularly focused on a specific clinical patient subset (del(5q) cytogenetics) and 2 epigenetic modulators (azacitidine and decitabine) having been approved for treating these patients. This article will review the mutational and biologic landscape of these disorders, as well as the targeted therapeutics currently in clinical trials that are focused on attacking these features. Given the molecular complexity of these disorders and the limited repertoire of effective therapeutic agents, we will also discuss novel approaches attempting to determine potentially effective and personalized treatment options through complementary chemosensitivity and computerized signaling network screening for these disparate MDS patient subsets. Translational use of such resources, combined with the rapidly evolving next-generation molecular technologies, should prove useful in effectuating improved and more selective options for therapy.
引用
- Aleshin A, Greenberg PL. Molecular pathophysiology of the myelodysplastic syndromes: insights for targeted therapy. Blood Adv. 2018. PMID: 30352953. doi:10.1182/bloodadvances.2018015834
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。